Full-Time

Director – Translational Science

Posted on 9/25/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$215.3k - $253.3kAnnually

Senior, Expert

San Carlos, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Cell or Molecular Biology (or a related discipline) with 10+ years industry experience
  • Experience in performing and critically analyzing and interpreting both pre-clinical and clinical data using different transcriptomic and proteomic techniques is required
  • Proven track-record of achievement, as evidenced by publications in peer-reviewed journals, authorship of patents, and internal and/or external scientific presentations
  • Ability to balance execution of tasks required to accomplish goals while creating an environment of scientific curiosity and open exchange of ideas
  • Display a consistently positive attitude with team members, scientific curiosity, and the drive to innovate and think creatively with courage, integrity and respect
Responsibilities
  • Design and analyze non-clinical experiments to understand the biological role of glucocorticoids in oncologic and neurologic indications
  • Generate decisional data via contract research vendors and academic collaborators
  • Partner with Research to discover and characterize novel biomarker endpoints in preclinical studies
  • Communicate findings with internal project teams, collaborators and public publications
  • Develop translational strategies and ensure biomarker-driven decision-making to support clinical development plans, the regulatory path, and product commercialization
  • Deliver subject matter expertise with respect to clinical biomarkers and other modalities as needed
  • Develop biomarker methods and analytically validate biomarkers for clinical use
  • Work with biomarker operations and clinical operations colleagues to ensure implementation of biomarker strategy through review of clinical protocols, contracts, eCRFs, DTAs, ICFs, lab manuals, TLFs, and CSRs
  • Conduct exploratory biomarker data analyses
  • Coordinate formal biomarker analyses with biometrics, biostatistics, clinical data management, and external biomarker analysis teams
  • Author patents, publications, and posters related to research activities
  • Partner with regulatory team to author/lead relevant nonclinical and clinical content for regulatory submissions, including INDs, IBs and NDAs etc
  • Adhere to agreed timelines and budgets to ensure timely and cost-effective execution of deliverables
  • Provide disease-biology expertise in cross functional teams and collaborate with other team members
  • Oversee global CRO vendor/partners ensuring that they optimally execute clinical and preclinical projects
  • Conduct resource planning and, as needed, hire and lead a team to support the objectives of the translational science group

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions. The goal of Corcept is to lead in cortisol modulation therapies and enhance the quality of life for patients suffering from disorders related to cortisol imbalance.

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in cortisol therapies boosts demand for Corcept's products.
  • Advancements in AI-driven drug discovery could accelerate Corcept's R&D processes.
  • Telemedicine expansion increases access to treatments like Korlym, broadening market reach.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market or regulatory changes.
  • Strategic shift to oncology may divert resources from core cortisol modulation focus.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE